Similarly, our data indicate that some cancer-associated DLC1 START mutants bind PS less efficiently than DLC1 WT, and that they display impaired inhibition of migration and anchorage-independent growth, without affecting DLC1 RhoGAP activity. This evidence concerns the gene ARHGAP1 and cancer.